363 related articles for article (PubMed ID: 26083950)
1. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C
Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950
[TBL] [Abstract][Full Text] [Related]
2. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma.
Wang X; Bayer ME; Chen X; Fredrickson C; Cornforth AN; Liang G; Cannon J; He J; Fu Q; Liu J; Nistor GI; Cao W; Chen C; Dillman RO
J Surg Oncol; 2015 Jun; 111(7):862-7. PubMed ID: 25873455
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
Dillman RO; Nayak SK; Barth NM; DeLeon C; Schwartzberg LS; Spitler LE; Church C; O'Connor AA; Beutel LD
Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
[TBL] [Abstract][Full Text] [Related]
7. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
8. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.
Vilella R; Benítez D; Milà J; Lozano M; Vilana R; Pomes J; Tomas X; Costa J; Vilalta A; Malvehy J; Puig S; Mellado B; Martí R; Castel T
Cancer Immunol Immunother; 2004 Jul; 53(7):651-8. PubMed ID: 14999431
[TBL] [Abstract][Full Text] [Related]
11. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Progression-Free and Overall Survival in Two Melanoma Patients Treated with Patient-Specific Therapeutic Vaccine Eltrapuldencel-T After Resection of a Solitary Liver Metastasis.
Dillman RO
Cancer Biother Radiopharm; 2016 Apr; 31(3):71-4. PubMed ID: 27093340
[TBL] [Abstract][Full Text] [Related]
13. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
[TBL] [Abstract][Full Text] [Related]
14. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma.
Dillman RO; DePriest C; DeLeon C; Barth NM; Schwartzberg LS; Beutel LD; Schiltz PM; Nayak SK
Cancer Biother Radiopharm; 2007 Jun; 22(3):309-21. PubMed ID: 17651037
[TBL] [Abstract][Full Text] [Related]
15. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma.
Hersey P; Halliday GM; Farrelly ML; DeSilva C; Lett M; Menzies SW
Cancer Immunol Immunother; 2008 Jul; 57(7):1039-51. PubMed ID: 18157724
[TBL] [Abstract][Full Text] [Related]
18. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW
Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
20. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma.
Dillman RO; DeLeon C; Beutel LD; Barth NM; Schwartzberg LS; Spitler LE; Garfield DH; O'Connor AA; Nayak SK
Crit Rev Oncol Hematol; 2001; 39(1-2):115-23. PubMed ID: 11418308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
